Creative Biolabs offers high-throughput isolation of Bifidobacterium adolescentis from well-characterized adult gut samples under rigorously controlled anaerobic conditions. We enrich for strains with strong colonization features, carbohydrate utilization breadth, and robust growth phenotypes, then rank B. adolescentis candidates using genomics and functional pre-screens for downstream development.
Our functional and MoA screening platform deciphers the mechanistic profile of Bifidobacterium adolescentis candidates. Assays include resistant starch and complex carbohydrate utilization, GABA and other metabolite quantification, and advanced in vitro models assessing epithelial barrier integrity to generate solid, quantitative MoA packages for B. adolescentis strain selection.
Creative Biolabs evaluates how Bifidobacterium adolescentis interacts with innate and adaptive immune cells using co-culture models, cytokine profiling, and T-cell polarization readouts. Particular focus is placed on Th17/Treg balance, myeloid activation signatures, and pattern-recognition receptor engagement to identify B. adolescentis strains with desirable immunomodulatory characteristics.
Our fermentation teams design strain-specific, strictly anaerobic, high-cell-density processes tailored to Bifidobacterium adolescentis. We optimize media composition, nitrogen sources, pH control, and redox balance from bench to pilot scale, enabling reproducible biomass production and metabolite generation suitable for preclinical studies and formulation development.
Creative Biolabs develops protective formulations for Bifidobacterium adolescentis, focusing on its sensitivity to oxygen and gastric stress. We screen multi-layer encapsulation strategies, cryoprotectant cocktails, and process parameters to maximize survival during freeze-drying, storage, and simulated gastrointestinal transit, supporting robust performance in downstream application studies.
Our stability testing service for Bifidobacterium adolescentis follows ICH-aligned conditions across long-term and accelerated protocols. We monitor viable counts and critical quality attributes in diverse carriers—including capsules, powders, dairy matrices, and oils—to generate evidence-based shelf-life projections and storage recommendations for B. adolescentis products.
Creative Biolabs performs comprehensive biological safety evaluations of Bifidobacterium adolescentis strains in line with GRAS/QPS expectations. Testing includes antibiotic resistance gene profiling, virulence factor screening, hemolysis assessment, and genome-level safety review, providing a clear safety dossier to support regulatory discussions and product positioning.
Our host-microbe interaction assays characterize adhesion of Bifidobacterium adolescentis to intestinal mucus and epithelial cells, competition with model pathogens, and modulation of barrier markers. These data clarify colonization advantages of selected B. adolescentis strains and their ability to influence the human gut microenvironment in physiologically relevant systems.
